GlassScriptPhysician profile
Ayesha Siddiqui
NPI 1114188109
$2,559.26
in general payments reported to CMS, 2019-2025
39 companies · $24.28 in 2025
The $24.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $417 · 2021: $631 · 2022: $860 · 2023: $488 · 2024: $140 · 2025: $24.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $441.09 | 2020-2024 | Prolia, Evenity |
| Lundbeck LLC | $280.52 | 2020-2024 | Vyepti |
| Daiichi Sankyo INC. | $225.89 | 2021-2024 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $184.58 | 2020-2022 | |
| Glaxosmithkline, LLC. | $105.89 | 2021-2023 | Ojjaara, Benlysta |
| Novartis Pharmaceuticals Corporation | $77.96 | 2020-2023 | |
| Genzyme Corporation | $74.06 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $71.52 | 2021-2022 | |
| Lilly USA, LLC | $70.13 | 2022-2023 | Retevmo, Jaypirca, Verzenio |
| Amag Pharmaceuticals, INC. | $69.51 | 2021-2022 | |
| Seagen INC. | $68.11 | 2020-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $67.97 | 2021-2022 | |
| Organon LLC | $59.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.65 | 2020-2023 | Enhertu |
| Teva Pharmaceuticals USA, INC. | $58.31 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.93 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.23 | 2022-2024 | Hyqvia |
| Shionogi INC | $44.92 | 2021-2022 | |
| Taiho Oncology, INC. | $40.84 | 2020-2023 | |
| Array Biopharma INC | $36.32 | 2022 | |
| Horizon Therapeutics Plc | $36.12 | 2022-2023 | Uplizna |
| Jazz Pharmaceuticals INC. | $30.74 | 2021 | |
| Abbvie INC. | $28.61 | 2022 | |
| Octapharma USA, INC. | $27.57 | 2020-2021 | |
| Celgene Corporation | $25.73 | 2022 | |
| Melinta Therapeutics, LLC | $24.67 | 2023 | Orbactiv, Kimyrsa, Vabomere |
| Global Blood Therapeutics, INC. | $23.77 | 2022 | |
| Puma Biotechnology, INC. | $22.97 | 2022 | |
| Incyte Corporation | $22.84 | 2020 | |
| Grifols USA, LLC | $20.57 | 2023 | Gamunex-C |
| Sobi, INC | $20.07 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2022 | |
| Merck Sharp & Dohme LLC | $19.01 | 2021 | |
| Astellas Pharma US INC | $18.18 | 2023 | |
| Karyopharm Therapeutics INC. | $17.30 | 2023 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $16.11 | 2023 | Sancuso |
| Gilead Sciences, INC. | $15.30 | 2021 | |
| Biogen, INC. | $15.14 | 2021 | |
| Epizyme, INC. | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.